Skip to main content

Advertisement

Table 1 CellSearch circulating tumor cell counts of samples from 10 patients with metastatic lung cancer, and the number of circulating tumor cells identified and sorted by fluorescence-activated cell sorting and successfully amplified

From: Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS

Patient Disease CellSearch- FACS- FACS- DNA- DNA-
identified identified sorted amplified amplified
CTC CTC CTC CTC WBC (%)
1 SCLC 81 34 (42%) 17 (21%) 17 (21%) 10 (100%)
2 SCLC 11 2 (18%) 3 (27%) 2 (18%) 10 (100%)
3 SCLC 3 3 (100%) 2 (67%) 2 (76%) 7 (70%)
4 NSCLC 4 2 (50%) 9 (225%) 0 (0%) 10 (100%)
5a NSCLC 8 6 (75%) 32 (400%) 3 (38%) 2 (20%)
6 SCLC 37 6 (16%) 5 (14%) 4 (11%) 10 (100%)
7 SCLC 23 9 (39%) 9 (39%) 6 (26%) 9 (90%)
8 SCLC 41 17 (41%) 17 (41%) 16 (39%) 8 (80%)
9 SCLC 44 3 (6.8%) 2 (4.5%) 2 (4.5%) 9 (90%)
10 NSCLC 0 1 1 1 10 (100%)
Total   252 83 (33%) 97 (39%) 52 (21%) 85 (85%)
  1. aThe first five samples were used to optimize the gates for patient CTC sorting. After five samples, the gates were set and not changed anymore. This table shows the CTC identified after the gates were changed, showing the number of CTC that would have been sorted with these gate settings. The number of sorted cells could be higher than 100% because there were more cells in the gate due to the initial gate setting. For each patient, 10 leukocytes were also sorted to serve as a control. CTC, circulating tumor cells; FACS, fluorescence-activated cell sorting; NSCLC: non-small-cell lung cancer; SCLC: small cell lung cancer; WBC, white blood cells.